Precision Kidney Diagnostics ("PKD" or the "Company") is a healthcare infrastructure company that has developed a compliance-first operating platform enabling Federally Qualified Health Centers (FQHCs) to integrate specialty care services — including rheumatology and infusion therapy — without assuming the associated regulatory exposure.

The Company's infrastructure-based revenue model eliminates dependency on drug spread arbitrage, instead generating predictable recurring revenue through contracted service arrangements with FQHC partners. PKD currently serves [X] FQHC locations across [X] states, with a demonstrable track record of expanding specialty care access to underserved populations while maintaining full compliance with 340B, Stark Law, Anti-Kickback Statute, and HRSA oversight requirements.

[Investment highlights and EBITDA narrative to be drafted by VP/Director]

Problem: FQHCs serve 30+ million patients annually but lack the infrastructure to deliver specialty care in-house. Patients requiring rheumatology, nephrology, or infusion therapy are referred to external specialists, creating care fragmentation, patient attrition, and missed 340B capture opportunities.

Solution: PKD provides a turnkey infrastructure layer that enables FQHCs to stand up specialty care service lines within their existing footprint. The Company handles clinical staffing, regulatory compliance, technology integration, and payer credentialing — allowing FQHCs to expand services without expanding their regulatory exposure.

Founded: [Year] | HQ: [City, State] | Employees: [X]

Source: Knowledge Graph entities [PKD, FQHCs, Specialty Care Integration] + regulatory mapping [340B, HRSA]

Total Addressable Market: 1,400+ FQHC organizations operating 14,000+ service delivery sites, serving 30.5 million patients (HRSA 2023 UDS data). Specialty care referral leakage estimated at $8.2B annually.

Serviceable Market: FQHCs with 5+ sites and annual revenue >$20M — approximately 340 organizations representing 6,200 sites.

Market Dynamics:
• 340B program under increasing legislative scrutiny — compliance-first operators gain advantage
• CMS pushing value-based care models favoring integrated specialty delivery
• FQHC consolidation trend creating larger, more sophisticated potential partners
• Competing models (drug spread-dependent) face regulatory headwinds

Source: HRSA UDS Data, CMS Reports, Knowledge Graph precedent [Deal #7, #22]

Revenue Model — Infrastructure-Based (No Drug Spread):

PKD generates revenue through contracted infrastructure service agreements with FQHC partners. Key revenue components include:
• Management Services Fees: Monthly per-site fees covering clinical operations, compliance oversight, and technology
• Staffing & Credentialing: Specialist staffing placement with payer enrollment management
• Technology Platform: Proprietary integration layer connecting FQHC EHR/PM systems with specialty workflows

Revenue Quality Indicators:
• 78% recurring revenue under multi-year contracts
• Net revenue retention: 112% (expansion within existing FQHC partners)
• No dependency on 340B drug spread — revenue persists regardless of 340B legislative changes

Source: Knowledge Graph [Infrastructure Revenue Model, Contract Recurring Revenue, No Drug Spread Dependency]

Auto-populated from Layer 2 — Regulatory Intelligence Engine

PKD operates at the intersection of multiple federal and state regulatory frameworks. The Company's compliance-first positioning is both its primary moat and its key risk management strategy.

Key Frameworks:
• 340B Drug Pricing Program: PKD enables FQHC partners to maintain 340B eligibility while expanding specialty services. The Company does not participate directly in 340B drug purchasing — eliminating spread-based revenue risk.
• Stark Law & AKS: All referral arrangements structured within established safe harbors. Fair market value documentation maintained for all compensation arrangements.
• HRSA Oversight: FQHC partners subject to ongoing HRSA compliance requirements. PKD's infrastructure model is designed to support — not complicate — HRSA compliance.

Source: Regulatory Intelligence Engine scorecard + Knowledge Graph [340B, Stark, AKS, HRSA, PPS]

Organic Growth Vectors:
1. Geographic Expansion: Replicate model in new states (licensure timeline: 60-120 days per state)
2. Specialty Line Extension: Add cardiology, endocrinology, dermatology to existing FQHC partnerships
3. Technology Monetization: License integration platform to FQHCs operating their own specialty programs

Inorganic Opportunity:
• PE roll-up thesis: Acquire regional specialty care enablers, integrate onto PKD platform
• Precedent: Deal #22 (2024) achieved 9.1x EBITDA for comparable infrastructure play

[Specific growth targets, timeline, and capital requirements to be added by Director]

This section is reserved for human authorship. The EBITDA narrative, financial projections, and quality-of-earnings analysis must be drafted by the deal team with direct access to management financials.

Acuity can pre-populate:
• Comparable transaction multiples from Knowledge Graph
• Revenue quality metrics framework
• Industry benchmark data (FQHC economics, specialty care margins)
• Regulatory risk adjustments to valuation

Investment highlights are the MD's domain. This is where the bank's thesis meets the buyer's criteria. Acuity provides the data foundation; the narrative is human.

Suggested framing from Knowledge Graph:
• Compliance moat in increasingly regulated landscape
• Infrastructure model = recurring, non-spread-dependent revenue
• 30M+ patient TAM with <5% current penetration
• Platform economics: each new FQHC partner is incremental margin